AREC Stock Overview
Arecor Therapeutics plc, a biopharmaceutical company, focuses on developing products in diabetes and other indications.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Arecor Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£1.37 |
| 52 Week High | UK£2.80 |
| 52 Week Low | UK£1.25 |
| Beta | -0.22 |
| 1 Month Change | -0.73% |
| 3 Month Change | -17.77% |
| 1 Year Change | -49.44% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -43.60% |
Recent News & Updates
Shareholder Returns
| AREC | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 6.2% | -0.2% | 2.3% |
| 1Y | -49.4% | -29.5% | 0.6% |
Return vs Industry: AREC underperformed the UK Biotechs industry which returned -29.8% over the past year.
Return vs Market: AREC underperformed the UK Market which returned 0.3% over the past year.
Price Volatility
| AREC volatility | |
|---|---|
| AREC Average Weekly Movement | 4.4% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: AREC has not had significant price volatility in the past 3 months.
Volatility Over Time: AREC's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 51 | Sarah Howell | arecor.com |
Arecor Therapeutics plc, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It also offers Ogluo, a ready-to-use glucagon auto-injector pen that is used to treat hypoglycaemia in patients with diabetes; and specialty hospital care products.
Arecor Therapeutics plc Fundamentals Summary
| AREC fundamental statistics | |
|---|---|
| Market cap | UK£41.81m |
| Earnings (TTM) | -UK£9.42m |
| Revenue (TTM) | UK£3.38m |
12.4x
P/S Ratio-4.4x
P/E RatioIs AREC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AREC income statement (TTM) | |
|---|---|
| Revenue | UK£3.38m |
| Cost of Revenue | UK£0 |
| Gross Profit | UK£3.38m |
| Other Expenses | UK£12.80m |
| Earnings | -UK£9.42m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 100.00% |
| Net Profit Margin | -278.81% |
| Debt/Equity Ratio | 0% |
How did AREC perform over the long term?
See historical performance and comparison